Clinical trial
Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or…
NCT00103103 · California Cancer Consortium, Other · Terminated
Key facts
| NCT number | NCT00103103 |
|---|---|
| Title | Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer |
| Official title | A Phase II Combination Trial of PS-341 and 5-FU/LV in Gastric and/or GE Junction Adenocarcinoma |
| Lead sponsor | California Cancer Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Cancer |
| Intervention type | Drug |
| Interventions | bortezomib, fluorouracil, leucovorin calcium |
| Start date | Mar 1, 2005 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Feb 8, 2005 |
| Last update posted | Oct 13, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: